Trial Profile
A prospectively randomized, phase III, multicenter, controlled trial to evaluate the safety and efficacy of the Zevalin [ibritumomab tiuxetan Y-90] therapeutic regimen plus Rituxan [rituximab] compared with Rituxan alone in patients with relapsed or refractory follicular NHL [non-Hodgkin's lymphoma]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Oct 2006 Status change
- 23 Sep 2005 New trial record.